Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure.
OBJECTIVE
Previous studies have demonstrated that an imbalance of matrix metalloproteinases (MMPs)/tissue inhibitors of metalloproteinase-1 (TIMP-1) and a loss of fibronectin are associated with postmyocardial infarction remodeling in rats. The present study was designed to examine this issue in patients with congestive heart failure (CHF).


METHODS
We measured plasma levels and the cardiac protein expression of MMPs/TIMP-1 and fibronectin in 39 patients with CHF and 38 controls.


RESULTS
Plasma levels of MMP-2, MMP-3, and MMP-9 tended to be higher in patients with CHF (NYHA II: 276 +/- 18, 613 +/- 118, and 245 +/- 43 microg/l, respectively; NYHA III: 302 +/- 20, 850 +/- 132, and 310 +/- 39 microg/l, respectively; NYHA IV: 367 +/- 15, 998 +/- 99, and 392 +/- 27 microg/l, respectively) than in controls (213 +/- 23, 485 +/- 102, and 158 +/- 31 microg/l, respectively), while the plasma TIMP-1 level tended to be lower in patients with CHF (NYHA II: 126 +/- 12 microg/l, NYHA III: 83 +/- 11 microg/l, and NYHA IV: 61 +/- 12 microg/l) than in controls (208 +/- 15 microg/l). Interestingly, the changes in protein expression of MMPs/TIMP-1 were consistent with their plasma concentration. Furthermore, the fibronectin level in the patients with CHF was significantly lower than in the controls.


CONCLUSIONS
These data suggest that human CHF is associated with an imbalance of MMPs/TIMP-1 and a concurrent loss of fibronectin.
Yang
Da-chun
DC
Department of Cardiology, General Hospital of PLA Chengdu Military Area Command, Chengdu, China.
Ma
Shuang-tao
ST
Tan
Yan
Y
Chen
Yi-hua
YH
Li
De
D
Tang
Bing
B
Chen
Jin-song
JS
Su
Xiao-hua
XH
Li
Gang
G
Zhang
Xin
X
Yang
Yong-jian
YJ
D000328:Adult; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006333:Heart Failure / Q000378:metabolism* / Q000473:pathology; D006349:Heart Valve Diseases / Q000378:metabolism / Q000473:pathology; D006352:Heart Ventricles / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D020782:Matrix Metalloproteinases / Q000097:blood*; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*
D005353:Fibronectins; D019715:Tissue Inhibitor of Metalloproteinase-1; D020782:Matrix Metalloproteinases; D019278:Matrix Metalloproteinase 3; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9